evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

29 questions · 34 findings · 2 reviews · Multiple Sclerosis and Rare Diseases of the CNS

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 7 · 20.6%GRADE not reported 2 · 5.9%Very low 8 · 23.5%Low 13 · 38.2%Moderate 4 · 11.8%High 0 · 0%

Rituximab vs placebo

Clinical relapse · relapsing multiple sclerosis

Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs other disease‐modifying treatments

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Rituximab vs other disease‐modifying treatments

Natalizumab · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).

2 findings from 1 review

Rituximab vs other disease‐modifying treatments

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Disability worsening · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).

1 finding from 1 review